Centenary Institute of Cancer Medicine & Cell Biology, Australia
Mark Gorrell has a PhD from Australian National University and conducted postdoctoral studies at University of Melbourne and Johns Hopkins University School of Medicine. He heads a liver disease pathogenesis, dipeptidyl peptidases and diabetes research group. He has authored 109 papers and patents, primarily on DPP4 and related proteases and on liver disease pathogenesis, is treasurer of the International Proteolysis Society and is on 3 editorial boards.
Mark D. Gorrell is devoted to understanding the functions of the dipeptidyl peptidase IV [DPP4] gene family enzymes and the molecular basis of chronic liver disease and how to exploit this knowledge to alleviate human illness. DPP4 is the target of a successful new type 2 diabetes therapy that is benefiting millions of patients. Improving understanding will lead to improved therapy for chronic liver disease sufferers, whether their illness is hepatitis B or C, autoimmune disease or fatty liver disease. Authorship: 106 publications including 5 patents, with about half the publications involving the dipeptidyl peptidase 4 gene family and most of the remainder on liver disease pathogenesis